ALS/FTD and related neurodegenerative diseases treatment methods

Neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) have been characterized by the expansion of the GGGGCC hexanucleotide repeat within the non-coding region of the human chromosome 9 open reading frame 72 (C9ORF72) gene. Previously, the impact of this genetic footprint on disease pathology is poorly understood, limiting the development of therapeutics against the diseases.

Researchers at Stanford's Lu laboratory have profiled the molecular impact of the peptides produced by the expansion of C9ORF72. The newly implicated pathways include molecular targets with known pharmacological agents that can be re-purposed and optimized, such as the antiporter nigericin or AKT activator SC79, where the inventors have demonstrated that pharmacological targeting can rescue ALS phenotypes in various animal models. Other pathways implicated by the inventors for their role in ALS and FTD, including AKT, Notch, and numerous mitochondrial proteins, can be manipulated by genetic modifiers or small molecules. This invention aims to reduce the cellular toxicity caused by the dipeptide repeat proteins produced from the expanded G4C2 repeats, potentially providing new treatment options for patients with C9ORF72-associated ALS/FTD and related neurodegenerative disorders, for which there are currently limited effective therapies.

Stage of Development: Research In Vivo